Centessa Pharmaceuticals (CNTA) Stock Statistics & Valuation Metrics

Centessa Pharmaceuticals has a market cap or net worth of $6.13B. The enterprise value is $6.08B.

Centessa Pharmaceuticals has 154,728,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Centessa Pharmaceuticals’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -32.22%.

The current PE Ratio of Centessa Pharmaceuticals is ―. Centessa Pharmaceuticals’s PEG ratio is 0.59.

In the last 12 months, Centessa Pharmaceuticals had revenue of 15.00M and earned -197.53M in profits. Earnings per share was -1.46.

In the last 12 months, operating cash flow was -208.79M and capital expenditures -371.00K, giving a free cash flow of -209.17M billion.

Centessa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Centessa Pharmaceuticals upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).

Centessa Pharmaceuticals as a current ratio of 8.57, with Debt / Equity ratio of 1.51%

In the past 12 months, Centessa Pharmaceuticals has paid 1.82M in taxes.

Centessa Pharmaceuticals EV to EBITDA ratio is -16.08, with an EV/FCF ratio of -17.20.

Centessa Pharmaceuticals has $276.59M in cash and marketable securities with $7.37M in debt, giving a net cash position of $269.22M billion.

Gross margin is 0.00%, with operating margin of -1384.61%, and net profit margin of -1316.88%.

The average price target for Centessa Pharmaceuticals is $42.40, which is 11.43% higher than the current price. The consensus rating is Hold